Tarceva - Small Molecule EGFR-Tyrosine Kinase Inhibitor for Cancer

 

Key Data:

Drug (Brand/Generic)
Tarceva (erlotinib)
Company/Licensee
OSI Pharmaceuticals, Genetech, Roche
Therapy Class
Anti-neoplastic agent
Product Description
EGFR-tyrosine kinase inhibitor
Current Indication
NSCLC
Market Sector
Oncology
Development Status
Approved in US, Europe and Japan



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development